CHI Advisors’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $13M | Buy |
407,633
+5,515
| +1% | +$176K | 5.15% | 7 |
|
|
2023
Q2 | $16.2M | Buy |
402,118
+141,059
| +54% | +$5.67M | 4.9% | 6 |
|
|
2023
Q1 | $11.1M | Buy |
261,059
+46,000
| +21% | +$1.96M | 2.96% | 7 |
|
|
2022
Q4 | $10.3M | Buy |
215,059
+14,830
| +7% | +$712K | 2.75% | 9 |
|
|
2022
Q3 | $7.53M | Buy |
200,229
+96,800
| +94% | +$3.64M | 2.03% | 10 |
|
|
2022
Q2 | $2.86M | Buy |
103,429
+41,200
| +66% | +$1.14M | 1.09% | 20 |
|
|
2022
Q1 | $3.38M | Buy |
62,229
+44,711
| +255% | +$2.43M | 1.44% | 18 |
|
|
2021
Q4 | $1.03M | Buy |
17,518
+4,891
| +39% | +$286K | 0.34% | 19 |
|
|
2021
Q3 | $500K | Sell |
12,627
-103,779
| -89% | -$4.11M | 0.15% | 19 |
|
|
2021
Q2 | $4.94M | Sell |
116,406
-284,062
| -71% | -$12.1M | 1.15% | 14 |
|
|
2021
Q1 | $24.6M | Sell |
400,468
-33,384
| -8% | -$2.05M | 4.93% | 7 |
|
|
2020
Q4 | $30.6M | Sell |
433,852
-135,606
| -24% | -$9.57M | 8.62% | 5 |
|
|
2020
Q3 | $22M | Sell |
569,458
-10,286
| -2% | -$397K | 7.81% | 5 |
|
|
2020
Q2 | $21.7M | Buy |
+579,744
| New | +$21.7M | 8.49% | 4 |
|